Screen for pre-eclampsia
CA 2522285 C · Owner: Savvidou, Makrina · Inventors: Savvidou, Makrina; Nicolaides, Kypros; Hingorani, Aroon
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
It has been demonstrated that the level of asymmetric dimethylarginine (ADMA) increases in women that subsequently develop pre-eclampsia or whose fetus subsequently develops intrauterine growth restriction (IUGR) and that ADMA plays a key role in the development of maternal hypertension. Accordingly the , level of ADMA in a pregnant woman can be used to determine whether or not a pregnant woman is at risk of developing pre-eclampsia or whether or not a fetus is at risk of developing IUGR. Furthermore antagonists of ADMA activity , are useful in the inhibition or prevention of pre-eclampsia or inhibition or prevention of IUGR.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 19, 2004 and granted January 22, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 19, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 19, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.